Nabriva therapeutics plc (NBRV)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Revenues:
Total revenue

789

-

6,920

-

1,703

-

461

-

-

-

1,468

1,051

-

-

-

-

-

Total revenue

-

-

-

525

-

-

-

847

7,551

-

-

-

1,678

-

-

-

-

Research premium and grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

971

1,785

1,419

Operating expenses:
Cost of product sales

8

-

15

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development expenses

4,944

5,202

5,601

8,074

7,538

21,488

40,804

9,717

10,279

13,244

12,668

11,043

12,660

12,957

12,058

9,943

13,036

Selling, general and administrative expenses

16,025

-

18,503

-

13,409

-

12,582

-

-

-

-

-

-

-

-

-

-

Total operating expenses

20,977

-

24,119

-

20,947

-

53,386

-

-

-

-

-

-

-

-

-

-

General and administrative

-

-

-

13,427

-

-

-

8,837

10,136

-

9,525

5,570

4,218

4,090

2,992

3,368

3,085

Total operating expenses

-

-

-

21,501

-

-

-

18,554

20,415

-

22,193

16,613

16,878

17,047

15,050

13,311

16,121

Loss from operations

-20,188

-22,070

-17,199

-20,976

-19,244

-30,879

-52,925

-17,707

-12,864

-22,281

-20,725

-15,562

-15,200

-14,740

-14,079

-11,526

-14,702

Other income (expense):
Other income (expense), net

798

99

-10

56

70

-100

-54

-141

23

-

301

-

-

-

-

-

-

Other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-116

206

-

50

-644

998

Interest income

64

79

94

72

10

10

11

19

9

16

69

112

121

109

92

54

88

Interest expense

1,024

1,132

709

904

899

114

8

7

4

-3

42

3

1

-

35

-

-

Loss on extinguishment of debt

-2,757

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss before income taxes

-23,107

-23,024

-17,824

-21,752

-20,063

-31,083

-52,976

-17,836

-12,836

-22,161

-20,397

-15,569

-14,874

-

-13,972

-12,116

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-13,616

Income tax expense

152

21

-29

-45

154

-258

-151

-48

506

101

1,872

-967

349

-671

28

-12

-17

Net loss

-23,259

-23,045

-17,795

-21,707

-20,217

-30,825

-52,825

-17,788

-13,342

-22,262

-22,269

-14,602

-15,223

-

-

-

-13,599

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-14,000

-12,104

-

Other comprehensive income (loss), net of tax
Unrealized losses on available-for-sale securities

-

-

-

-

-

-

-

-

-

-69

69

-10

-16

-85

34

-8

41

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-13,966

-12,112

-

Other comprehensive income, net of tax

-

-

-

-

-

-

-

-

-

-26

69

-10

-16

-

34

-8

-

Other comprehensive income (loss), net of tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

41

Comprehensive loss

-

-

-

-

-

-

-

-

-

-22,288

-22,200

-14,612

-15,239

-

-

-

-13,558

Loss per share
Basic and Diluted ($ per share)

-0.25

-0.29

-0.24

-0.30

-0.29

-0.56

-0.90

-0.44

-0.36

-0.60

-0.79

-0.54

-0.56

-

-0.66

-0.57

-

Basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6.42

Diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6.42

Weighted average number of shares:
Basic and Diluted

94,595

80,408

75,161

72,526

68,701

67,312

58,442

40,515

36,911

36,784

28,147

27,186

27,204

-

21,276

21,252

-

Basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,117

Diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,117

Product revenue, net
Total revenue

156

-

1,445

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue
Total revenue

-

-

-

-

-

-

-

0

6,500

-

-

-

-

-

-

-

-

Total revenue

145

-

5,051

-

1,000

-

-

-

-

-

-

-

-

-

-

-

-

Research premium and grant revenue
Total revenue

-

-

-

525

-

-

-

847

1,051

-

-

-

-

-

-

-

-

Total revenue

488

-

424

-

703

-

461

-

-

-

-

-

-

-

-

-

-